PART I ITEM 1. B USINESS BUSINESS Overview We are a biotechnology company that uses our robust, chemistry-driven approach and drug discovery capabilities to discover and develop small molecule drugs for virology and immunology indications. Virology: We discovered glecaprevir, the second of two antiviral protease inhibitors developed through our collaboration with AbbVie for the treatment of acute or chronic infection with hepatitis C virus, or HCV. Glecaprevir is co-formulated as part of AbbVies...
Q2 FY2026 — expected 2026-09-21
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-19 | 2025-09-30 | 0001193125-25-288121 | EDGAR | 73K words |
| 2024-11-27 | 2024-09-30 | 0000950170-24-131260 | EDGAR | — |
| 2023-11-22 | 2023-09-30 | 0000950170-23-065884 | EDGAR | — |
| 2022-11-23 | 2022-09-30 | 0000950170-22-025667 | EDGAR | — |
| 2021-11-24 | 2021-09-30 | 0000950170-21-004895 | EDGAR | — |
| 2020-11-25 | 2020-09-30 | 0001564590-20-055233 | EDGAR | — |
| 2019-11-27 | 2019-09-30 | 0001564590-19-044729 | EDGAR | — |
| 2018-11-29 | 2018-09-30 | 0001564590-18-030275 | EDGAR | — |
| 2017-12-11 | 2017-09-30 | 0001564590-17-024794 | EDGAR | — |
| 2016-12-09 | 2016-09-30 | 0001193125-16-789660 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-12 | 2026-06-30 | 0001193125-26-345719 | EDGAR | — |
| 2026-02-11 | 2025-12-31 | 0001193125-26-046502 | EDGAR | 17K words |
| 2025-08-13 | 2025-06-30 | 0001193125-25-179795 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0000950170-25-071340 | EDGAR | — |
| 2025-02-12 | 2024-12-31 | 0000950170-25-018810 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0000950170-24-092714 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055581 | EDGAR | — |
| 2024-02-08 | 2023-12-31 | 0000950170-24-012796 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039754 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019842 | EDGAR | — |
| 2023-02-08 | 2022-12-31 | 0000950170-23-002134 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0000950170-22-015515 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-10 | 0001193125-26-342336 | EDGAR | — |
| 2026-03-26 | 0001193125-26-125113 | EDGAR | 1K words |
| 2026-03-12 | 0001193125-26-104109 | EDGAR | — |
| 2026-02-09 | 0001193125-26-042812 | EDGAR | — |
| 2025-11-17 | 0001193125-25-284633 | EDGAR | — |
| 2025-10-01 | 0001193125-25-226828 | EDGAR | — |
| 2025-09-29 | 0001193125-25-221791 | EDGAR | — |
| 2025-09-29 | 0001193125-25-221527 | EDGAR | — |
| 2025-08-27 | 0001193125-25-189691 | EDGAR | — |
| 2025-08-20 | 0001193125-25-183719 | EDGAR | — |
189 total filings indexed. 157 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001177648 |
| Ticker | ENTA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Website | https://www.enanta.com |
| Listed | 2013-03-21 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ENTA (~200 tokens, structured JSON with cryptographic provenance)